These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15241439)

  • 21. Roles of transforming growth factor-β in graft-versus-host and graft-versus-tumor effects.
    Carli C; Giroux M; Delisle JS
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1329-40. PubMed ID: 22326303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor regulatory T cells identified by FoxP3 expression but also by the membranous CD4+CD127low/neg phenotype influence graft-versus-tumor effect after donor lymphocyte infusion.
    Hicheri Y; Bouchekioua A; Hamel Y; Henry A; Rouard H; Pautas C; Beaumont JL; Kuentz M; Cordonnier C; Cohen JL; Maury S
    J Immunother; 2008; 31(9):806-11. PubMed ID: 18833007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives.
    Zeiser R; Bertz H; Spyridonidis A; Houet L; Finke J
    Bone Marrow Transplant; 2004 Dec; 34(11):923-8. PubMed ID: 15361911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Ladaique P; Castagna L; Faucher C; Granata A; Oudin C; Lemarie C; Calmels B; Stoppa AM; Schiano De Colella JM; Duran S; Chabannon C; Blaise D
    Exp Hematol; 2012 Jul; 40(7):521-7. PubMed ID: 22446605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect.
    Byrne JL; Carter GI; Ellis I; Haynes AP; Russell NH
    Bone Marrow Transplant; 1997 Sep; 20(6):517-20. PubMed ID: 9313888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.
    van Bergen CA; Kester MG; Jedema I; Heemskerk MH; van Luxemburg-Heijs SA; Kloosterboer FM; Marijt WA; de Ru AH; Schaafsma MR; Willemze R; van Veelen PA; Falkenburg JH
    Blood; 2007 May; 109(9):4089-96. PubMed ID: 17234742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
    Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
    Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eruption of lymphocyte recovery or autologous graft-versus-host disease?
    Nellen RG; van Marion AM; Frank J; Poblete-Gutiérrez P; Steijlen PM
    Int J Dermatol; 2008 Nov; 47 Suppl 1():32-4. PubMed ID: 18986483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multidonor bone marrow transplantation improves donor engraftment and increases the graft versus tumor effect while decreasing graft-versus-host disease.
    Zhanna Y; Ester H; Lola W; Offer G; Shimon S; Shapira MY
    Transpl Int; 2011 Feb; 24(2):194-200. PubMed ID: 20854413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma.
    Dodero A; Perfetti V; Ciceri F; Corradini P
    Haematologica; 2002 Dec; 87(12):ECR41. PubMed ID: 12495912
    [No Abstract]   [Full Text] [Related]  

  • 33. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
    van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM
    Bone Marrow Transplant; 2006 Jun; 37(12):1135-41. PubMed ID: 16757975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report.
    Rondelli D; Bandini G; Cavo M; Re F; Motta M; Senese B; Leopardi G; Stanzani M; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(6):685-7. PubMed ID: 10490737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteasome inhibitor clioquinol as a candidate drug in prophylaxis and treatment of acute graft-versus-host disease.
    Liang Y; Mao X; Liu H
    Med Hypotheses; 2011 Mar; 76(3):400-2. PubMed ID: 21122999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting.
    Galimberti S; Benedetti E; Morabito F; Fazzi R; Pacini S; Andreazzoli F; Martino M; Iacopino P; Petrini M
    Transpl Immunol; 2005 Dec; 15(2):173-7. PubMed ID: 16412962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
    Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.